• Ahn HS, Lee SK, Kim HJ, Jang JY, Joo KR, Dong SH, Kim BH, Lee JI, Chang YW, Chang R 2006 Risk of postoperative infection in patients with inflammatory bowel disease. Korean J. Gastroenterol. 48: 306-312.

• Akobeng A, Thomas A 2007 Enteral nutrition for maintenance of remission in Crohn's disease. Cochrane Database Syst. Rev. 3: CD005984. *

• Allorge D, Hamdan R, Broly F, Libersa C, Colombel JF 2005 ITPA genotyping test does not improve detection of Crohn's disease patients at risk of azathioprine/6-mercaptopurine induced myelosuppression. Gut 54: 565. *

• Alves A, Panis Y, Joly F, Pocard M, Lavergne-Slove A, Bouhnik Y, Valleur P 2004 Could immunosuppressive drugs reduce recurrence rate after second resection for Crohn disease? Inflamm. Bowel Dis. 10: 491-495. *

• Ananthakrishnan AN, Attila T, Otterson MF, Lipchik RJ, Massey BT, Komorowski RA, Binion DG 2007 Severe pulmonary toxicity after azathioprine/6-mercaptopurine initiation for the treatment of inflammatory bowel disease. J. Clin. Gastroenterol. 41: 682-688.

• Andoh A, Tsujikawa T, Ban H, Hashimoto T, Bamba S, Ogawa A, Sasaki M, Saito Y, Fujiyama Y 2008 Monitoring 6-thioguanine nucleotide concentrations in Japanese patients with inflammatory bowel disease. J. Gastroenterol. Hepatol. Jul 23 [Epub ahead of print].

• Ansari A, Aslam Z, DE Sica A, Smith M, Gilshenan K, Fairbanks L, Marinaki A, Sanderson J, Duley J 2008 The influence of xanthine oxidase on thiopurine metabolism in Crohn's disease. Aliment. Pharmacol. Ther. 28: 749-757. *

• Aranda R, Horgan K 1998 Immunosuppressive drugs in the treatment of inflammatory bowel disease. Semin. Gastrointest. Dis. 9: 2-9.

• Arnott ID, Watts D, Satsangi J 2003 Azathioprine and anti-TNF alpha therapies in Crohn's disease: a review of pharmacology, clinical efficacy and safety. Pharmacol. Res. 47: 1-10. *

• Baert FJ, Rutgeerts PJ 2000 Medical therapies for ulcerative colitis and Crohn's disease. Curr. Gastroenterol. Rep. 2: 446-450.

• Barnes BH, Borowitz SM, Saulsbury FT, Hellems M, Sutphen JL 2004 Discordant erythrocyte sedimentation rate and C-reactive protein in children with inflammatory bowel disease taking azathioprine or 6-mercaptopurine. J. Pediatr. Gastroenterol. Nutr. 38: 509-512. *

• Bastida Pa G, Nos Mate P, Aguas Peri M, Beltran Niclas B, Rodriguez Sole M, Ponce Garcia J 2007 Optimization of immunomodulatory treatment with azathioprine or 6-mercaptopurine in inflammatory bowel disease. Gastroenterol. Hepatol. 30: 511-516.

• Biancone L, Orlando A, Kohn A, Colombo E, Sostegni R, Angelucci E, Rizzello F, Castiglione F, Benezzato L, Papi C, Meucci G, Riegler G, Mocciaro F, Geremia A, Calabrese E, Cottone M, Pallone F 2006 Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched-pair study. Gut 55: 228-233. *

• Biancone L, Tosti C, Fina D, Fantini M, De Nigris F, Geremia A, Pallone F 2003 Review article: maintenance treatment of Crohn's disease. Aliment. Pharmacol. Ther. 17 Suppl. 2: 31-37.

• Bickston SJ, Comerford LW, Cominelli F 2003 Future therapies for inflammatory bowel disease. Curr. Gastroenterol. Rep. 5: 518-523.

• Bitton A 2005 Preventing postoperative recurrence in Crohn's disease with 6-mercaptopurine and azathioprine: approaching the cutting edge. Inflamm. Bowel Dis. 11: 513-514. *

• Boulton-Jones JR, Pritchard K, Mahmoud AA 2000 The use of 6-mercaptopurine in patients with inflammatory bowel disease after failure of azathioprine therapy. Aliment. Pharmacol. Ther. 14: 1561-1565. *

• Bousvaros A, Guandalini S, Baldassano RN, Botelho C, Evans J, Ferry GD, Goldin B, Hartigan L, Kugathasan S, Levy J, Murray KF, Oliva-Hemker M, Rosh JR, Tolia V, Zholudev A, Vanderhoof JA, Hibberd PL 2005 A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease. Inflamm. Bowel Dis. 11: 833-839. *

• Bratcher JM, Korelitz BI 2006 Toxicity of infliximab in the course of treatment of Crohn's disease. Expert Opin. Drug Saf. 5: 9-16.

• Brookes MJ, Green JR 2004 Maintenance of remission in Crohn's disease: current and emerging therapeutic options. Drugs 64: 1069-1089.

• Brown SJ, Mayer L 2007 The immune response in inflammatory bowel disease. Am. J. Gastroenterol. 102: 2058-2069. *

• Brynskov J, Feagan BG, Jewell D, McDonald JWD, Stange EF 2004 Cyclosporine for maintenance of remission in Crohn’s disease. Cochrane Database Syst. Rev. 2: CD004377. *

• Calvet X, Gallardo O, Coronas R, Casellas F, Montserrat A, Torrejon A, Vergara M, Campo R, Brullet E 2006 Remission on thiopurinic immunomodulators normalizes quality of life and psychological status in patients with Crohn's disease. Inflamm. Bowel Dis. 12: 692-696. *

• Caprilli R, Angelucci E, Cocco A, Viscido A, Annese V, Ardizzone S, Biancone L, Castiglione F, Cottone M, Meucci G, Paoluzi P, Papi C, Sturniolo GC, Vecchi M 2005 Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement. Dig. Liver Dis. 37: 407-417.

• Chande N, Ponich T, Gregor J 2005 A survey of Canadian gastroenterologists about the use of methotrexate in patients with Crohn's disease. Can. J. Gastroenterol. 19: 553-558.

• Cho J 2000 Update on inflammatory bowel disease genetics. Curr. Gastroenterol. Rep. 2: 434-439.

• Choi PM, Targan SR 1994 Immunomodulator therapy in inflammatory bowel disease. Dig. Dis. Sci. 39: 1885-1892.

• Cohen RD 2002 Evolving medical therapies for ulcerative colitis. Curr. Gastroenterol. Rep. 4: 497-505.

• Cohen RD, Tsang JF, Hanauer SB 2000 Infliximab in Crohn's disease: first anniversary clinical experience. Am. J. Gastroenterol. 95: 3469-3477. *

• Colombel JF, Loftus EV Jr, Tremaine WJ, Pemberton JH, Wolff BG, Young-Fadok T, Harmsen WS, Schleck CD, Sandborn WJ 2004 Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy. Am. J. Gastroenterol. 99: 878-883. *

• Cottone M, Orlando A, Modesto I 2006 Postoperative maintenance therapy for inflammatory bowel disease. Curr. Opin. Gastroenterol. 22: 377-381.

• Cox KL, Cox KM 1998 Oral vancomycin: treatment of primary sclerosing cholangitis in children with inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 27: 580-583.

• Cuffari C 2006 Inflammatory bowel disease in children: a pediatrician's perspective. Minerva Pediatr. 58: 139-157.

• Cuffari C, Dassopoulos T, Turnbough L, Thompson RE, Bayless TM 2004 Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 2: 410-417. *

• Cuffari C, Hunt S, Bayless T 2001 Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut 48: 642-646. *

• Cuffari C, Hunt S, Bayless TM 2000 Enhanced bioavailability of azathioprine compared to 6-mercaptopurine therapy in inflammatory bowel disease: correlation with treatment efficacy. Aliment. Pharmacol. Ther. 14: 1009-1014. *

• Cuffari C, Li DY, Mahoney J, Barnes Y, Bayless TM 2004 Peripheral blood mononuclear cell DNA 6-thioguanine metabolite levels correlate with decreased interferon-gamma production in patients with Crohn's disease on AZA therapy. Dig. Dis. Sci. 49: 133-137. *

• D'Haens G 2004 Optimizing the use of current drugs in IBD. Falk Symposium 140. Inflammatory Bowel Disease: Translation from Basic Research to Clinical Practice. Dubrovnik (Croatia). p. 65. May 7-8. *

• D'Haens G, Daperno M 2002 Advances in medical therapy for Crohn's disease. Curr. Gastroenterol. Rep. 4: 506-512.

• D'Haens G, Hlavaty T 2004 Advances in medical therapy for Crohn's disease. Curr. Gastroenterol. Rep. 6: 496-505.

• de Boer NK, Van Elburg RM, Wilhelm AJ, Remmink AJ, Van Vugt JM, Mulder CJ, Van Bodegraven AA 2005 6-Thioguanine for Crohn's disease during pregnancy: thiopurine metabolite measurements in both mother and child. Scand. J. Gastroenterol. 40: 1374-1377. *

• De La Rue SA, Bickston SJ 2006 Evidence-based medications for the treatment of the inflammatory bowel diseases. Curr. Opin. Gastroenterol. 22: 365-369.

• Decker GA, Loftus EV Jr, Pasha TM, Tremaine WJ, Sandborn WJ 2001 Crohn's disease of the esophagus: clinical features and outcomes. Inflamm. Bowel Dis. 7: 113-119. *

• Derijks LJ, Gilissen LP, Hooymans PM, Hommes DW 2006 Review article: thiopurines in inflammatory bowel disease. Aliment. Pharmacol. Ther. 24: 715-729. *

• Devlin SM, Hu B, Ippoliti A 2007 Mucormycosis presenting as recurrent gastric perforation in a patient with Crohn's disease on glucocorticoid, 6-mercaptopurine, and infliximab therapy. Dig. Dis. Sci. 52: 2078-2081. *

• Dhillon S, Loftus EV 2005 Medical therapy of Crohn's disease. Curr. Treat. Options Gastroenterol. 8: 19-30.

• Domenech E 2006 Inflammatory bowel disease: current therapeutic options. Digestion 73 Suppl. 1: 67-76.

• Domenech E, Nos P, Papo M, Lopez-San Roman A, Garcia-Planella E, Gassull MA 2005 6-Mercaptopurine in patients with inflammatory bowel disease and previous digestive intolerance of azathioprine. Scand. J. Gastroenterol. 40: 52-55. *

• Dubinsky MC 2003 Optimizing immunomodulator therapy for inflammatory bowel disease. Curr. Gastroenterol. Rep. 5: 506-511.

• Dubinsky MC, Fleshner PP 2003 Treatment of Crohn's disease of inflammatory, stenotic, and fistulizing phenotypes. Curr. Treat. Options Gastroenterol. 6: 183-200.

• Dubinsky MC, Hassard PV, Seidman EG, Kam LY, Abreu MT, Targan SR, Vasiliauskas EA 2001 An open-label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6-mercaptopurine therapy. Inflamm. Bowel Dis. 7: 181-189. *

• Dubinsky MC, Reyes E, Ofman J, Chiou CF, Wade S, Sandborn WJ 2005 A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Am. J. Gastroenterol. 100: 2239-2247. *

• Duley JA, Florin TH 2005 Thiopurine therapies: problems, complexities, and progress with monitoring thioguanine nucleotides. Ther. Drug Monit. 27: 647-654.

• Dupont B, Dupont C, Justum AM, Piquet MA, Reimund JM 2008 Enteral nutrition in adult Crohn's disease: present status and perspectives. Mol. Nutr. Food Res. 52: 875-884. *

• Eidelwein AP, Cuffari C, Abadom V, Oliva-Hemker M 2005 Infliximab efficacy in pediatric ulcerative colitis. Inflamm. Bowel Dis. 11: 213-218. *

• Elliott PR, Moore GT, Bell SJ, Connell WR 2005 Severe recurrent Crohn's disease of the ileocolonic anastomosis disappearing completely with antibacterial therapy. Gut 54: 1818-1819. *

• Escher JC, Taminiau JA, Nieuwenhuis EE, Buller HA, Grand RJ 2003 Treatment of inflammatory bowel disease in childhood: best available evidence. Inflamm. Bowel Dis. 9: 34-58. *

• Feagan BG 2003 Maintenance therapy for inflammatory bowel disease. Am. J. Gastroenterol. 98: S6-S17. *

• Feagan BG 2005 Management of perianal and fistulizing disease. Falk Symposium 146: GUT-LIVER INTERACTIONS: BASIC AND CLINICAL CONCEPTS, Innsbruck (Austria), March 11-12, 2005, p. 37. *

• Fishman SJ, Feins NR, D' Amato RJ, Folkman J 1999 Long-term remission of Crohn's disease treated with thalidomide: a seminal case report. Angiogenesis 3: 201-204. *

• Friedman S 2007 Medical therapy and birth outcomes in women with Crohn's disease: what should we tell our patients? Am. J. Gastroenterol. 102: 1414-1416.

• Friedman S, Marion JF, Scherl E, Rubin PH, Present DH 2001 Intravenous cyclosporine in refractory pyoderma gangrenosum complicating inflammatory bowel disease. Inflamm. Bowel Dis. 7: 1-7. *

• Froehlich F, Juillerat P, Pittet V, Felley C, Mottet C, Vader JP, Michetti P, Gonvers JJ 2007 Maintenance of surgically induced remission of Crohn's disease. Digestion 76: 130-135.

• Galandiuk S, Davis BR 2008 Infliximab-induced disseminated histoplasmosis in a patient with Crohn's disease. Nat. Clin. Pract. Gastroenterol Hepatol. 5: 283-287.

• Geier DL, Miner PB Jr 1992 New therapeutic agents in the treatment of inflammatory bowel disease. Am. J. Med. 93: 199-208.

• Gerber NL, Steinberg AD 1976 Clinical use of immunosuppressive drugs: part II. Drugs 11: 90-112.

• Ghosh S, Chaudhary R, Carpani M, Playford RJ 2006 Is thiopurine therapy in ulcerative colitis as effective as in Crohn's disease? Gut 55: 6-8. *

• Gilissen LP, Derijks LJ, Verhoeven HM, Bierau J, Hooymans PM, Hommes DW, Engels LG 2007 Pancytopenia due to high 6-methylmercaptopurine levels in a 6-mercaptopurine treated patient with Crohn's disease. Dig. Liver Dis. 39: 182-186.

• Gisbert JP, Gomollon F, Cara C, Luna M, Gonzalez-Lama Y, Pajares JM, Mate J, Guijarro LG 2005 Thiopurine methyltransferase activity in the inflammatory bowel disease. A study on 7046 Spanish patients. Med. Clin. (Barc.) 125: 281-285.

• Gisbert JP, Luna M, Mate J, Gonzalez-Guijarro L, Cara C, Pajares JM 2006 Choice of azathioprine or 6-mercaptopurine dose based on thiopurine methyltransferase (TPMT) activity to avoid myelosuppression. A prospective study. Hepatogastroenterology 53: 399-404.

• Glazier KD, Palance AL, Griffel LH, Das KM 2005 The ten-year single-center experience with 6-mercaptopurine in the treatment of inflammatory bowel disease. J. Clin. Gastroenterol. 39: 21-26.

• Goldstein ES, Marion JF, Present DH 2004 6-Mercaptopurine is effective in Crohn's disease without concomitant steroids. Inflamm. Bowel Dis. 10: 79-84. *

• Goldstein F 1987 Immunosuppressant therapy of inflammatory bowel disease. Pharmacologic and clinical aspects. J. Clin. Gastroenterol. 9: 654-658.

• Gonvers JJ, Juillerat P, Mottet C, Felley C, Burnand B, Vader JP, Michetti P, Froehlich F 2005 Maintenance of remission in Crohn's disease. Digestion 71: 41-48.

• Gonvers JJ, Juillerat P, Mottet C, Pittet V, Felley C, Vader JP, Michetti P, Froehlich F 2007 Maintenance of medically induced remission of Crohn's disease. Digestion 76: 116-129.

• Gonzalez-Lama Y, Abreu L, Vera MI, Pastrana M, Tabernero S, Revilla J, Duran JG, Escartin P 2005 Long-term oral tacrolimus therapy in refractory to infliximab fistulizing Crohn's disease: a pilot study. Inflamm. Bowel Dis. 11: 8-15. *

• Gupta G, Lautenbach E, Lewis JD 2006 Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 4: 1483-1490.

• Gutkowski K, Bilkiewicz T 2006 Experimental methods in the treatment of Lesniowski-Crohn disease. Pol. Merkuriusz. Lek. 20: 457-461.

• Hait EJ, Bousvaros A, Schuman M, Shamberger RC, Lillehei CW 2007 Pouch outcomes among children with ulcerative colitis treated with calcineurin inhibitors before ileal pouch anal anastomosis surgery. J. Pediatr. Surg. 42: 31-34.

• Hanauer SB 2004 Optimal approach to perianal Crohn's disease. Falk Symposium 140. Inflammatory Bowel Disease: Translation from Basic Research to Clinical Practice. Dubrovnik (Croatia). p. 75. May 7-8. *

• Hanauer SB 1999 Medical therapy for Crohn's disease. Curr. Opin. Gastroenterol. 15: 308.

• Hanauer SB 2003 Assessing the risk of lymphomas in inflammatory bowel disease. Rev. Gastroenterol. Disord. 3: 50-51. *

• Hanauer SB, Korelitz BI, Rutgeerts P, Peppercorn MA, Thisted RA, Cohen RD, Present DH 2004 Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology 127: 723-729. *

• Hanauer SB, Present DH 2003 The state of the art in the management of inflammatory bowel disease. Rev. Gastroenterol. Disord. 3: 81-92. *

• Hande S, Wilson-Rich N, Bousvaros A, Zholudev A, Maurer R, Banks P, Makrauer F, Reddy S, Burakoff R, Friedman S 2006 5-Aminosalicylate therapy is associated with higher 6-thioguanine levels in adults and children with inflammatory bowel disease in remission on 6-mercaptopurine or azathioprine. Inflamm. Bowel Dis. 12: 251-257. *

• Hassard PV, Vasiliauskas EA, Kam LY, Targan SR, Abreu MT 2000 Efficacy of mycophenolate mofetil in patients failing 6-mercaptopurine or azathioprine therapy for Crohn's disease. Inflamm. Bowel Dis. 6: 16-20. *

• Hayee BH, Harris AW 2005 6-Mercaptopurine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology 128: 249. *

• Heller T, James SP, Drachenberg C, Hernandez C, Darwin PE 1999 Treatment of severe esophageal Crohn's disease with infliximab. Inflamm. Bowel Dis. 5: 279-282. *

• Heuschkel R 2005 Synergy between immunosuppressive therapy and enteral nutrition in the management of childhood Crohn's disease. JPEN J. Parenter. Enteral Nutr. 29: S160-S165.

• Hibi T, Naganuma M, Kitahora T, Kinjyo F, Shimoyama T 2003 Low-dose azathioprine is effective and safe for maintenance of remission in patients with ulcerative colitis. J. Gastroenterol. 38: 740-746. *

• Hilsden RJ, Verhoef MJ, Best A, Pocobelli G 2003 A national survey on the patterns of treatment of inflammatory bowel disease in Canada. BMC Gastroenterol. 3: 10. *

• Hindorf U, Lindqvist M, Peterson C, Soderkvist P, Strom M, Hjortswang H, Pousette A, Almer S 2006 Pharmacogenetics during standardised initiation of thiopurine therapy in inflammatory bowel disease. Gut 55: 1423-1431. *

• Homan M, Baldassano RN, Mamula P 2005 Managing complicated Crohn's disease in children and adolescents. Nat. Clin. Pract. Gastroenterol. Hepatol. 2: 572-579. *

• Hommes DW, Oldenburg B, van Bodegraven AA, van Hogezand RA, de Jong DJ, Romberg-Camps MJ, van der Woude J, Dijkstra G 2006 Guidelines for treatment with infliximab for Crohn's disease. Neth. J. Med. 64: 219-229. *

• Hyams JS 2005 Use of 6-mercaptopurine/azathioprine as the immunomodulator of choice for moderately active Crohn's disease: pro. Inflamm. Bowel Dis. 11: 197-199. *

• Hyams JS, Markowitz JF 2005 Can we alter the natural history of Crohn disease in children? J. Pediatr. Gastroenterol. Nutr. 40: 262-272. *

• Isaacs KL 2007 Crohn's disease of the esophagus. Curr. Treat. Options Gastroenterol. 10: 61-70.

• Jacobstein DA, Baldassano RN 2005 Use of 6-mercaptopurine/azathioprine as the immunomodulator of choice for moderately active Crohn's disease: balance. Inflamm. Bowel Dis. 11: 203-205. *

• Jacobstein DA, Mamula P, Markowitz JE, Leonard M, Baldassano RN 2006 Predictors of immunomodulator use as early therapy in pediatric Crohn's disease. J. Clin. Gastroenterol. 40: 145-148.

• Jaspers GJ, Verkade HJ, Escher JC, de Ridder L, Taminiau JA, Rings EH 2006 Azathioprine maintains first remission in newly diagnosed pediatric Crohn's disease. Inflamm. Bowel Dis. 12: 831-836. *

• Jeshion WC, Larsen KL, Jawad AF, Piccoli DA, Verma R, Maller ES, Baldassano RN 2000 Azathioprine and 6-mercaptopurine for the treatment of perianal Crohn's disease in children. J. Clin. Gastroenterol. 30: 294-298.

• Juffermans NP, Jager A, Kersten MJ, van Oers MH, Hommes DW 2005 Epstein-Barr virus-related lymphomas in patients with inflammatory bowel disease. Ned. Tijdschr. Geneeskd. 149: 1859-1863.

• Juillerat P, Mottet C, Froehlich F, Felley C, Vader JP, Burnand B, Gonvers JJ, Michetti P 2005 Extraintestinal manifestations of Crohn's disease. Digestion 71: 31-36.

• Juillerat P, Mottet C, Pittet V, Froehlich F, Felley C, Gonvers JJ, Vader JP, Michetti P 2007 Extraintestinal manifestations of Crohn's disease. Digestion 76: 141-148.

• Juillerat P, Pittet V, Felley C, Mottet C, Froehlich F, Vader JP, Gonvers JJ, Michetti P 2007 Drug safety in Crohn's disease therapy. Digestion 76: 161-168.

• Kakrida M, Orengo I, Markus R 2005 Sudden onset of multiple nevi after administration of 6-mercaptopurine in an adult with Crohn's disease: a case report. Int. J. Dermatol. 44: 334-336.

• Kane S, Cohen SM, Hart J 2004 Acute sinusoidal obstruction syndrome after 6-thioguanine therapy for Crohn's disease. Inflamm. Bowel Dis. 10: 652-654. *

• Katz JA 2002 Advances in the medical therapy of inflammatory bowel disease. Curr. Opin. Gastroenterol. 18: 435-440.

• Katz JA 2007 Management of inflammatory bowel disease in adults. J. Dig. Dis. 8: 65-71.

• Katz JA 2004 Pregnancy and inflammatory bowel disease. Curr. Opin. Gastroenterol. 20: 328-332.

• Katz JA, Antoni C, Keenan GF, Smith DE, Jacobs SJ, Lichtenstein GR 2004 Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am. J. Gastroenterol. 99: 2385-2392. *

• Kaur N, Mahl TC 2007 Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases. Dig. Dis. Sci. 52: 1481-1484. *

• Kim KH, Lichtenstein GR 2004 Refractory inflammatory bowel disease. Curr. Treat. Options Gastroenterol. 7: 201-211.

• Kinney T, Rawlins M, Kozarek R, France R, Patterson D 2003 Immunomodulators and "on demand" therapy with infliximab in Crohn's disease: clinical experience with 400 infusions. Am. J. Gastroenterol. 98: 608-612. *

• Kirsner JB 1991 Inflammatory bowel disease. Part II: Clinical and therapeutic aspects. Dis. Mon. 37: 669-746.

• Kirsner JB 1991 Inflammatory bowel disease. Part I: Nature and pathogenesis. Dis. Mon. 37: 605-666.

• Kooros K, Katz AJ 2004 Infliximab therapy in pediatric Crohn's pouchitis. Inflamm. Bowel Dis. 10: 417-420. *

• Korelitz BI, Mirsky FJ, Fleisher MR, Warman JI, Wisch N, Gleim GW 1999 Malignant neoplasms subsequent to treatment of inflammatory bowel disease with 6-mercaptopurine. Am. J. Gastroenterol. 94: 3248-3253. *

• Kozuch PL, Hanauer SB 2008 Treatment of inflammatory bowel disease: a review of medical therapy. World J. Gastroenterol. 14: 354-377. *

• Kruis W 2005 Crohn's disease - standards of treatment 2004. Schweiz. Rundsch. Med. Prax. 94: 1595-1598.

• Kubota D, Takishima C, Ishii K, Kawamura T, Matsumoto T, Itsui Y, Okada E, Chin S, Oooka S, Tsuchiya K, Araki A, Sakamoto N, Miyata T, Kanai T, Watanabe M 2006 A case report: severe bone marrow suppression caused by 6-mercaptopurine in Crohn's disease patient. Nippon Shokakibyo Gakkai Zasshi 103: 1044-1049.

• Kugathasan S 2001 Pediatric inflammatory bowel disease: clinical and therapeutic aspects. Curr. Opin. Gastroenterol. 17: 350-355.

• Kung SJ, Choudhary C, McGeady SJ, Cohn JR 2006 Lack of cross-reactivity between 5-aminosalicylic acid-based drugs: a case report and review of the literature. Ann. Allergy Asthma Immunol. 97: 284-287.

• Kunitake H, Hodin R, Shellito PC, Sands BE, Korzenik J, Bordeianou L 2008 Perioperative treatment with infliximab in patients with Crohn's disease and ulcerative colitis is not associated with an increased rate of postoperative complications. J. Gastrointest. Surg. Aug 12 [Epub ahead of print]. *

• Lamers CB, Griffioen G, van Hogezand RA, Veenendaal RA 1999 Azathioprine: an update on clinical efficacy and safety in inflammatory bowel disease. Scand. J. Gastroenterol. Suppl. 230: 111-115. *

• Lashner BA 1992 Risk factors for small bowel cancer in Crohn's disease. Dig. Dis. Sci. 37: 1179-1184.

• Lashner BA 2003 Clinical advances in ulcerative colitis. American College of Gastroenterology 68th Annual Scientific Meeting and Postgraduate Course, October 10 - 15, 2003, Baltimore, Maryland.

• Lecomte T, Contou JF, Beaugerie L, Carbonnel F, Cattan S, Gendre JP, Cosnes J 2003 Predictive factors of response of perianal Crohn's disease to azathioprine or 6-mercaptopurine. Dis. Colon Rectum 46: 1469-1475.

• Legnani PE, Kornbluth A 2001 Immunomodulator therapy in inflammatory bowel disease. Curr. Treat. Options Gastroenterol. 4: 199-205.

• Lemann M 2004 Which immunomodulator for Crohn's disease? Falk Symposium 140. Inflammatory Bowel Disease: Translation from Basic Research to Clinical Practice. Dubrovnik (Croatia). p. 74. May 7-8. *

• Lemann M 2007 Treatment of chronic inflammatory bowel diseases. Bull. Acad. Natl. Med. 191: 1125-1141.

• Lemann M, Mary JY, Duclos B, Veyrac M, Dupas JL, Delchier JC, Laharie D, Moreau J, Cadiot G, Picon L, Bourreille A, Sobahni I, Colombel JF; Groupe d'Etude Therapeutique des Affections Inflammatoires du Tube Digestif (GETAID) 2006 Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology 130: 1054-1061. *

• Levine JS, Burakoff R 2007 Chemoprophylaxis of colorectal cancer in inflammatory bowel disease: current concepts. Inflamm. Bowel Dis. 13: 1293-1298.

• Levy C, Tremaine WJ 2002 Management of internal fistulas in Crohn's disease. Inflamm. Bowel Dis. 8: 106-111. *

• Lichtenstein GR 2001 Approach to corticosteroid-dependent and corticosteroid-refractory Crohn's disease. Inflamm. Bowel Dis. 7 Suppl. 1: S23-S29. *

• Lichtenstein GR, Abreu MT, Cohen R, Tremaine W 2006 American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 130: 935-939. *

• Lichtenstein GR, Abreu MT, Cohen R, Tremaine W 2006 American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 130: 940-987. *

• Lichtenstein GR, Bala M, Han C, DeWoody K, Schaible T 2002 Infliximab improves quality of life in patients with Crohn's disease. Inflamm. Bowel Dis. 8: 237-243. *

• Lindqvist M, Hindorf U, Almer S, Soderkvist P, Strom M, Hjortswang H, Peterson C 2006 No induction of thiopurine methyltransferase during thiopurine treatment in inflammatory bowel disease. Nucleosides Nucleotides Nucleic Acids 25: 1033-1037. *

• Linn FV, Peppercorn MA 1992 Drug therapy for inflammatory bowel disease: Part II. Am. J. Surg. 164: 178-185.

• Listrom C, Holt K 2004 Inflammatory bowel disease. Emerg. Med. 36: 24-28.

• Lobel EZ, Korelitz BI, Vakher K, Panagopoulos G 2004 Prolonged remission of severe Crohn's disease after fever and leukopenia caused by 6-mercaptopurine. Dig. Dis. Sci. 49: 336-338. *

• Lobel EZ, Korelitz BI, Xuereb MA, Panagopoulos G 2004 A search for the optimal duration of treatment with 6-mercaptopurine for ulcerative colitis. Am. J. Gastroenterol. 99: 462-465. *

• Lowry PW, Franklin CL, Weaver AL, Szumlanski CL, Mays DC, Loftus EV, Tremaine WJ, Lipsky JJ, Weinshilboum RM, Sandborn WJ 2001 Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide. Gut 49: 656-664. *

• Lowry PW, Weaver AL, Tremaine WJ, Sandborn WJ 1999 Combination therapy with oral tacrolimus (FK506) and azathioprine or 6-mercaptopurine for treatment-refractory Crohn's disease perianal fistulae. Inflamm. Bowel Dis. 5: 239-245. *

• Mack DR 1998 Ongoing advances in inflammatory bowel diseases, including maintenance therapies, biologic agents, and biology of disease. Curr. Opin. Pediatr. 10: 499-506.

• Madsen JR, Laursen LS, Lauritsen K 1992 Chronic inflammatory bowel disease - current status. Ugeskr. Laeger. 154: 2243-2250.

• Mahadevan U, Marion JF, Present DH 2003 Fistula response to methotrexate in Crohn's disease: a case series. Aliment. Pharmacol. Ther. 18: 1003-1008. *

• Mahadevan U, Sandborn WJ 2001 Evolving medical therapies for Crohn's disease. Curr. Gastroenterol. Rep. 3: 471-476.

• Mardini HE 2005 Azathioprine and 6-mercaptopurine in postoperative maintenance of Crohn's disease remission: is no evidence of effect an evidence of no effect? Gastroenterology 128: 246-248. *

• Markowitz JF 2003 Therapeutic efficacy and safety of 6-mercaptopurine and azathioprine in patients with Crohn's disease. Rev. Gastroenterol. Disord. 3 Suppl. 1: S23-S29. *

• Marx G, Seidman EG 1999 Inflammatory bowel disease in pediatric patients. Curr. Opin. Gastroenterol. 15: 322.

• Masunaga Y, Ohno K, Ogawa R, Hashiguchi M, Echizen H, Ogata H 2007 Meta-analysis of risk of malignancy with immunosuppressive drugs in inflammatory bowel disease. Ann. Pharmacother. 41: 21-28.

• McGovern DP, Jewell DP 2005 Risks and benefits of azathioprine therapy. Gut 54: 1055-1059. *

• McKaig B, Stack W 1998 Novel approaches to inflammatory bowel disease. Expert Opin. Investig. Drugs 7: 1099-1113.

• Moskovitz DN, Bodian C, Chapman ML, Marion JF, Rubin PH, Scherl E, Present DH 2004 The effect on the fetus of medications used to treat pregnant inflammatory bowel-disease patients. Am. J. Gastroenterol. 99: 656-661. *

• Mottet C, Juillerat P, Gonvers JJ, Froehlich F, Burnand B, Vader JP, Michetti P, Felley C 2005 Pregnancy and Crohn's disease. Digestion 71: 54-61.

• Mottet C, Juillerat P, Pittet V, Gonvers JJ, Froehlich F, Vader JP, Michetti P, Felley C 2007 Pregnancy and breastfeeding in patients with Crohn's disease. Digestion 76: 149-160.

• Moum B 2000 Medical treatment: does it influence the natural course of inflammatory bowel disease? Eur. J. Intern. Med. 11: 197-203.

• Myrelid P, Svarm S, Andersson P, Almer S, Bodemar G, Olaison G 2006 Azathioprine as a postoperative prophylaxis reduces symptoms in aggressive Crohn's disease. Scand. J. Gastroenterol. 41: 1190-1195. *

• Nagy F, Molnar T, Szepes Z, Farkas K, Nyari T, Lonovics J 2008 Efficacy of 6-mercaptopurine treatment after azathioprine hypersensitivity in inflammatory bowel disease. World J. Gastroenterol. 14: 4342-4346. *

• Navarro FA, Hanauer SB, Kirschner BS 2007 Effect of long-term low-dose prednisone on height velocity and disease activity in pediatric and adolescent patients with Crohn disease. J. Pediatr. Gastroenterol. Nutr. 45: 312-318.

• Newby E, Sawczenko A, Thomas A, Wilson D 2005 Interventions for growth failure in childhood Crohn's disease. Cochrane Database Syst. Rev. 3: CD003873. *

• Ng SC, Arebi N, Kamm MA 2007 Medium-term results of oral tacrolimus treatment in refractory inflammatory bowel disease. Inflamm. Bowel Dis. 13: 129-134. *

• Nguyen GC, Harris ML, Dassopoulos T 2006 Insights in immunomodulatory therapies for ulcerative colitis and Crohn's disease. Curr. Gastroenterol. Rep. 8: 499-505.

• Nielsen OH, Vainer B, Bregenholt S, Claesson MH, Bishop PD, Kirman I 1997 Inflammatory bowel disease: potential therapeutic strategies. Cytokines Cell. Mol. Ther. 3: 267-281.

• Nielsen OH, Vainer B, Rask-Madsen J 2001 Review article: the treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine. Aliment. Pharmacol. Ther. 15: 1699-1708. *

• Norgard B, Pedersen L, Christensen LA, Sorensen HT 2007 Therapeutic drug use in women with Crohn's disease and birth outcomes: a Danish nationwide cohort study. Am. J. Gastroenterol. 102: 1406-1413. *

• Ochsenkuhn T, Sackmann M, Goke B 2003 Inflammatory bowel diseases (IBD) - critical discussion of etiology, pathogenesis, diagnostics, and therapy. Radiologe 43: 1-8.

• Oefferlbauer-Ernst A, Reinisch W, Miehsler W, Vogelsang H, Dejaco C 2004 Healthy offspring in parents both receiving thiopurines. Gastroenterology 126: 628. *

• Ojiro K, Naganuma M, Ebinuma H, Kunimoto H, Tada S, Ogata H, Iwao Y, Saito H, Hibi T 2008 Reactivation of hepatitis B in a patient with Crohn's disease treated using infliximab. J. Gastroenterol. 43: 397-401.

• Oliva-Hemker MM, Abadom V, Cuffari C, Thompson RE 2007 Nonadherence with thiopurine immunomodulator and mesalamine medications in children with Crohn disease. J. Pediatr. Gastroenterol. Nutr. 44: 180-184. *

• Panaccione R, Rutgeerts P, Sandborn WJ, Feagan B, Schreiber S, Ghosh S 2008 Review article: treatment algorithms to maximise remission and minimise corticosteroid dependence in patients with inflammatory bowel disease: a time bound approach. Aliment. Pharmacol. Ther. 28: 674-688. *

• Panaccione R; Canadian Consensus Group on the use of infliximab in Crohn's disease 2001 Infliximab for the treatment of Crohn's disease: review and indications for clinical use in Canada. Can. J. Gastroenterol. 15: 371-375.

• Parsi MA, Lashner BA, Achkar JP, Connor JT, Brzezinski A 2004 Type of fistula determines response to infliximab in patients with fistulous Crohn's disease. Am. J. Gastroenterol. 99: 445-449. *

• Pierik M, Rutgeerts P, Vlietinck R, Vermeire S 2006 Pharmacogenetics in inflammatory bowel disease. World J. Gastroenterol. 12: 3657-3667. *

• Plevy SE 2002 Corticosteroid-sparing treatments in patients with Crohn's disease. Am. J. Gastroenterol. 97: 1607-1617. *

• Punati J, Markowitz J, Lerer T, Hyams J, Kugathasan S, Griffiths A, Otley A, Rosh J, Pfefferkorn M, Mack D, Evans J, Bousvaros A, Moyer MS, Wyllie R, Oliva-Hemker M, Mezoff A, Leleiko N, Keljo D, Crandall W; Pediatric IBD Collaborative Research Group 2008 Effect of early immunomodulator use in moderate to severe pediatric Crohn disease. Inflamm. Bowel Dis. 14: 949-954.

• Rajapakse R, Korelitz BI 2001 Inflammatory bowel disease during pregnancy. Curr. Treat. Options Gastroenterol. 4: 245-251.

• Reddy SI, Friedman S, Telford JJ, Strate L, Ookubo R, Banks PA 2005 Are patients with inflammatory bowel disease receiving optimal care? Am. J. Gastroenterol. 100: 1357-1361. *

• Ringheanu M, Markowitz J 2002 Inflammatory bowel disease in children. Curr. Treat. Options Gastroenterol. 5: 181-196.

• Rizzello F, Gionchetti P, Venturi A, Morselli C, Campieri M 2002 Review article: the management of refractory Crohn's disease. Aliment. Pharmacol. Ther. 16 Suppl. 4: 40-47. *

• Robinson M 1997 Optimizing therapy for inflammatory bowel disease. Am. J. Gastroenterol. 92: 12S-17S.

• Robinson M 1998 Medical therapy of inflammatory bowel disease for the 21st century. Eur. J. Surg. Suppl. 582: 90-98.

• Rulyak SJ, Saunders MD, Lee SD 2003 Hepatotoxicity associated with 6-thioguanine therapy for Crohn's disease. J. Clin. Gastroenterol. 36: 234-237.

• Rumiantsev VG, Rogozina VA, Osina VA 2004 Immunosuppressive therapy of inflammatory diseases of the large intestine. Eksp. Klin. Gastroenterol. 6: 89-98, 165.

• Rutgeerts P, Van Assche G, Vermeire S 2004 Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 126: 1593-1610. *

• Rutgeerts PJ 2001 Conventional treatment of Crohn's disease: objectives and outcomes. Inflamm. Bowel Dis. 7 Suppl. 1: S2-S8. *

• Rutgeerts PJ 2004 An historical overview of the treatment of Crohn's disease: why do we need biological therapies? Rev. Gastroenterol. Disord. 4 Suppl. 3: S3-S9. *

• Sack DM, Peppercorn MA 1983 Drug therapy of inflammatory bowel disease. Pharmacotherapy 3: 158-176.

• Sandborn W, Sutherland L, Pearson D, May G, Modigliani R, Prantera C 2000 Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane Database Syst. Rev. 2: CD000545. *

• Sandborn WJ 2003 Optimizing anti-tumor necrosis factor strategies in inflammatory bowel disease. Curr. Gastroenterol. Rep. 5: 501-505.

• Sandborn WJ 2003 Evidence-based treatment algorithm for mild to moderate Crohn's disease. Am. J. Gastroenterol. 98: S1-S5. *

• Sandborn WJ 1998 Azathioprine: state of the art in inflammatory bowel disease. Scand. J. Gastroenterol. Suppl. 225: 92-99. *

• Sandborn WJ 2000 Steroid-dependent Crohn's disease. Can. J. Gastroenterol. 14 Suppl. C: 17C-22C.

• Sandborn WJ, Feagan BG 2004 The efficacy of azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in patients with Crohn's disease remains uncertain. Gastroenterology 127: 990-993. *

• Sandborn WJ, Hanauer SB 2002 Infliximab in the treatment of Crohn's disease: a user's guide for clinicians. Am. J. Gastroenterol. 97: 2962-2972. *

• Sartor RB 2003 Clinical applications of advances in the genetics of IBD. Rev. Gastroenterol. Disord. 3 Suppl. 1: S9-S17. *

• Sawada K, Kusugami K, Suzuki Y, Bamba T, Munakata A, Hibi T, Shimoyama T 2005 Leukocytapheresis in ulcerative colitis: results of a multicenter double-blind prospective case-control study with sham apheresis as placebo treatment. Am. J. Gastroenterol. 100: 1362-1369. *

• Schroder O, Stein J 2003 Low dose methotrexate in inflammatory bowel disease: current status and future directions. Am. J. Gastroenterol. 98: 530-537. *

• Schwartz DA, White CM, Wise PE, Herline AJ 2005 Use of endoscopic ultrasound to guide combination medical and surgical therapy for patients with Crohn's perianal fistulas. Inflamm. Bowel Dis. 11: 727-732. *

• Scribano M, Prantera C 2003 Review article: medical treatment of moderate to severe Crohn's disease. Aliment. Pharmacol. Ther. 17 Suppl. 2: 23-30.

• Seibold F 2003 Does conservative therapy of chronic inflammatory bowel diseases still play a role? Swiss Surg. 9: 127-130.

• Seidman EG 2000 Recent advances in the diagnosis and treatment of pediatric inflammatory bowel disease. Curr. Gastroenterol. Rep. 2: 248-252.

• Selby W 2000 Pathogenesis and therapeutic aspects of Crohn's disease. Vet. Microbiol. 77: 505-511. *

• Shin SJ, Collins MT 2008 Thiopurine drugs (azathioprine and 6-mercaptopurine) inhibit Mycobacterium paratuberculosis growth in vitro. Antimicrob. Agents Chemother. 52: 418-426. *

• Sohi S, Cohen RD 2006 Management of refractory ulcerative colitis. Curr. Treat. Options Gastroenterol. 9: 234-245.

• Soon SY, Ansari A, Yaneza M, Raoof S, Hirst J, Sanderson JD 2004 Experience with the use of low-dose methotrexate for inflammatory bowel disease. Eur. J. Gastroenterol. Hepatol. 16: 921-926.

• Sparrow MP, Hande SA, Friedman S, Cao D, Hanauer SB 2007 Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin. Gastroenterol. Hepatol. 5: 209-214.

• Spradlin NM, Wise PE, Herline AJ, Muldoon RL, Rosen M, Schwartz DA 2008 A randomized prospective trial of endoscopic ultrasound to guide combination medical and surgical treatment for Crohn's perianal fistulas. Am. J. Gastroenterol. Jul 18 [Epub ahead of print]. *

• Stange EF 2006 Immunosuppressors in inflammatory bowel disease. Falk Symposium 154: INFLAMMATORY BOWEL DISEASE - DIAGNOSTIC AND THERAPEUTIC STRATEGIES, Moscow (Russia), June 9 - 10, 2006, p. 53. *

• Stein RB, Hanauer SB 1998 Medical management of Crohn's disease. Drugs Today (Barc.) 34: 541-548.

• Steinhart H 2000 Maintenance therapy in Crohn's disease. Can. J. Gastroenterol. 14 Suppl. C: 23C-28C.

• Stotland BR, Lichtenstein GR 1998 Newer treatments for inflammatory bowel disease. Drugs Today (Barc.) 34: 177-192.

• Su CG, Stein RB, Lewis JD, Lichtenstein GR 2000 Azathioprine or 6-mercaptopurine for inflammatory bowel disease: do risks outweigh benefits? Dig. Liver Dis. 32: 518-531.

• Summers RW, Elliott DE, Urban JF Jr, Thompson R, Weinstock JV 2005 Trichuris suis therapy in Crohn’s disease. Gut 54: 87-90. *

• Sun JH, Das KM 2005 Low-dose oral methotrexate for maintaining Crohn's disease remission: where we stand. J. Clin. Gastroenterol. 39: 751-756.

• Sutherland LR 2000 Prevention of relapse of Crohn's disease. Inflamm. Bowel Dis. 6: 321-328. *

• Tanis AA 1998 Azathioprine in inflammatory bowel disease, a safe alternative? Mediators Inflamm. 7: 141-144. *

• Teml A, Schwab M, Harrer M, Miehsler W, Schaeffeler E, Dejaco C, Mantl M, Schneider B, Vogelsang H, Reinisch W 2005 A prospective, open-label trial of 6-thioguanine in patients with ulcerative or indeterminate colitis. Scand. J. Gastroenterol. 40: 1205-1213. *

• Torok HP, Goke B, Konrad A 2008 Pharmacogenetics of Crohn's disease. Pharmacogenomics 9: 881-893.

• Tremaine WJ 1997 Refractory IBD: medical management. Neth. J. Med. 50: S12-S14.

• Turner D, Grossman AB, Rosh J, Kugathasan S, Gilman AR, Baldassano R, Griffiths AM 2007 Methotrexate following unsuccessful thiopurine therapy in pediatric Crohn's disease. Am. J. Gastroenterol. 102: 2804-2812. *

• Uhlen S, Belbouab R, Narebski K, Goulet O, Schmitz J, Cezard JP, Turck D, Ruemmele FM 2006 Efficacy of methotrexate in pediatric Crohn's disease: a French multicenter study. Inflamm. Bowel Dis. 12: 1053-1057. *

• Vasiliauskas E 2003 Recent advances in the diagnosis and classification of inflammatory bowel disease. Curr. Gastroenterol. Rep. 5: 493-500.

• Warman JI, Korelitz BI, Fleisher MR, Janardhanam R 2003 Cumulative experience with short- and long-term toxicity to 6-mercaptopurine in the treatment of Crohn's disease and ulcerative colitis. J. Clin. Gastroenterol. 37: 220-225.

• Wichan P, Chojnacki J, Wojtun S 2004 Immunotherapy of inflammatory bowel diseases. Pol. Merkuriusz. Lek. 17 Suppl. 1: 40-43.

• Yamamoto T 2005 Factors affecting recurrence after surgery for Crohn's disease. World J. Gastroenterol. 11: 3971-3979. *

• Yenson PR, Forrest D, Schmiegelow K, Dalal BI 2007 Azathioprine-associated acute myeloid leukemia in a patient with Crohn's disease and thiopurine S-methyltransferase deficiency. Am. J. Hematol. 83: 80-83. *

• Yip JS, Woodward M, Abreu MT, Sparrow MP 2008 How are azathioprine and 6-mercaptopurine dosed by gastroenterologists? Results of a survey of clinical practice. Inflamm. Bowel Dis. 14: 514-518.

Number of references = 230

www psc-literature.org